212 related articles for article (PubMed ID: 34681049)
41. Urinary 5-Hydroxyindolacetic Acid Measurements in Patients with Neuroendocrine Tumor-Related Carcinoid Syndrome: State of the Art.
Rossi RE; Lavezzi E; Jaafar S; Cristofolini G; Laffi A; Nappo G; Carrara S; Bertuzzi AF; Uccella S; Repici A; Zerbi A; Lania AGA
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627093
[TBL] [Abstract][Full Text] [Related]
42. Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: A Comprehensive Literature Review.
Yazdanpanah O; Surapaneni S; Shanah L; Kabashneh S
Cureus; 2021 Mar; 13(3):e14006. PubMed ID: 33884247
[TBL] [Abstract][Full Text] [Related]
43. Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms.
Modlin IM; Kidd M; Filosso PL; Roffinella M; Lewczuk A; Cwikla J; Bodei L; Kolasinska-Cwikla A; Chung KM; Tesselaar ME; Drozdov IA
J Thorac Dis; 2017 Nov; 9(Suppl 15):S1458-S1473. PubMed ID: 29201449
[TBL] [Abstract][Full Text] [Related]
44. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors.
Genç CG; Jilesen APJ; Nieveen van Dijkum EJM; Klümpen HJ; van Eijck CHJ; Drozdov I; Malczewska A; Kidd M; Modlin I
J Surg Oncol; 2018 Jul; 118(1):37-48. PubMed ID: 30114319
[TBL] [Abstract][Full Text] [Related]
45. Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future.
Komarnicki P; Musiałkiewicz J; Stańska A; Maciejewski A; Gut P; Mastorakos G; Ruchała M
J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233409
[TBL] [Abstract][Full Text] [Related]
46. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
47. Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany.
Hörsch D; Schmid KW; Anlauf M; Darwiche K; Denecke T; Baum RP; Spitzweg C; Grohé C; Presselt N; Stremmel C; Heigener DF; Serke M; Kegel T; Pavel M; Waller CF; Deppermann KM; Arnold R; Huber RM; Weber MM; Hoffmann H
Oncol Res Treat; 2014; 37(5):266-76. PubMed ID: 24853787
[TBL] [Abstract][Full Text] [Related]
48. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
[TBL] [Abstract][Full Text] [Related]
49. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
[TBL] [Abstract][Full Text] [Related]
50. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total
Tirosh A; Papadakis GZ; Millo C; Sadowski SM; Herscovitch P; Pacak K; Marx SJ; Yang L; Nockel P; Shell J; Green P; Keutgen XM; Patel D; Nilubol N; Kebebew E
Eur J Endocrinol; 2017 May; 176(5):575-582. PubMed ID: 28289088
[TBL] [Abstract][Full Text] [Related]
51. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
52. Inflammatory Cytokines Associated with Diagnosis, Tumor Grade and Prognosis in Patients with Neuroendocrine Tumors.
Geisler L; Hellberg T; Lambrecht J; Jann H; Knorr J; Eschrich J; Loosen SH; Wree A; Hammerich L; Krieg A; Luedde T; Tacke F; Roderburg C; Mohr R
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294509
[TBL] [Abstract][Full Text] [Related]
53. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
[TBL] [Abstract][Full Text] [Related]
54. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
Bajetta E; Ferrari L; Martinetti A; Celio L; Procopio G; Artale S; Zilembo N; Di Bartolomeo M; Seregni E; Bombardieri E
Cancer; 1999 Sep; 86(5):858-65. PubMed ID: 10463986
[TBL] [Abstract][Full Text] [Related]
55. INSM1, a Novel Biomarker for Detection of Neuroendocrine Neoplasms: Cytopathologists' View.
Maleki Z; Nadella A; Nadella M; Patel G; Patel S; Kholová I
Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943408
[TBL] [Abstract][Full Text] [Related]
56. Insulinoma-associated protein 1 immunostaining for various types of neuroendocrine tumors on FNA smears.
Hou T; Gan Q; Joseph CT; Sun X; Gong Y
Cancer Cytopathol; 2020 Oct; 128(10):725-732. PubMed ID: 32573984
[TBL] [Abstract][Full Text] [Related]
57. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
[TBL] [Abstract][Full Text] [Related]
58. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.
Peracchi M; Conte D; Gebbia C; Penati C; Pizzinelli S; Arosio M; Corbetta S; Spada A
Eur J Endocrinol; 2003 Jan; 148(1):39-43. PubMed ID: 12534356
[TBL] [Abstract][Full Text] [Related]
59. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F
Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
Yang Z; Klimstra DS; Hruban RH; Tang LH
Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
